2A Biosciences is a drug discovery company developing Serotonergic Anti-Inflammatories (SAIs) — non-hallucinogenic 5-HT2A receptor agonists that harness the peripheral anti-inflammatory properties of psychedelics without behavioural effects. Co-founded by pharmacologists Charles D. Nichols and David E. Nichols, the company's near-term programs target dermatological inflammatory conditions, with a broader platform addressing autoimmune and cardiovascular disease. The company has completed an oversubscribed seed round backed by biotech and psychedelic VCs.
Drug Pipeline
1SAI NCEs
Non-hallucinogenic 5-HT2A agonists as Serotonergic Anti-Inflammatories (SAIs). Near-term focus on dermatology; broader pipeline targeting asthma, autoimmune, and cardiovascular inflammatory diseases. Co-founded by Charles D. Nichols and David E. Nichols (LSU).
Quick Facts
- Type
- Private Biotech
- Lead Stage
- Discovery
- Website
- Visit